Skip to main content
Algernon Health Inc. logo

Algernon Health Inc. — Investor Relations & Filings

Ticker · AGN ISIN · CA3978841078 CSE Human health and social work activities
Open in API
Filings indexed 579 across all filing types
Latest filing 2021-07-30 Capital/Financing Update
Country CA Canada
Listing CSE AGN

About Algernon Health Inc.

https://www.algernonhealth.com/

Algernon Health Inc. is a healthcare company focused on the provision of advanced diagnostic services, primarily through the establishment of medical clinics specializing in Alzheimer's disease. A key offering is the utilization of brain-optimized Positron Emission Tomography (PET) scanning technology for screening and imaging within a planned network of North American facilities. The company maintains a clinical-stage drug development and repurposing division, which investigates existing, approved drugs for new therapeutic applications targeting unmet global medical needs.

Recent filings

Filing Released Lang Actions
52-109FV2 - Certification of interim filings - CEO (E).pdf
Capital/Financing Update Classification · 95% confidence The document is a detailed pricing supplement related to a securities offering by Banque Nationale du Canada. It includes terms of the offering, descriptions of the securities, risk factors, pricing, and conditions of the notes (titres sous forme de billets). The text references a base prospectus and supplements, and it is clearly a legal and financial disclosure document related to a public offering of debt securities. It is not a financial report, earnings release, management discussion, or any other type of corporate filing related to financial performance or governance. Instead, it is a capital markets document related to the issuance of securities and their terms. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document is lengthy (15,000 characters) and contains substantive information about the offering, not just an announcement or a brief notice, so it is not an RPA or RNS. Therefore, the correct classification is CAP with high confidence.
2021-07-30 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate by the CFO of Algernon Pharmaceuticals Inc. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended May 31, 2021. The document is primarily an officer certification letter, not the interim report itself. It explicitly states it is a certification and does not include the financial statements or substantive financial data. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS), not as the interim report (IR). The document length is short (3159 characters), consistent with a certification letter rather than a full report.
2021-07-30 English
Interim MD&A - English.pdf
Regulatory Filings
2021-07-30 English
Interim financial statements/report – English.pdf
Regulatory Filings
2021-07-30 English
News release - English.pdf
Regulatory Filings
2021-07-08 English
News release - English.pdf
Regulatory Filings
2021-07-06 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.